Velpatasvir/sofosbuvir

Velpatasvir/sofosbuvir
Combination of
Velpatasvir NS5A inhibitor
Sofosbuvir NS5B (RNA polymerase) inhibitor
Clinical data
Trade names Epclusa, Sofosvel
AHFS/Drugs.com epclusa
Pregnancy
category
  • US: B (No risk in non-human studies)
Routes of
administration		 Oral
Legal status
Legal status

Velpatasvir/sofosbuvir (trade name Epclusa) is a two-drug combination for the treatment of hepatitis C. It is administered as a single daily pill containing the viral NS5A inhibitor velpatasvir and sofosbuvir, a nucleotide inhibitor of the viral RNA polymerase. It is the first treatment, that works for all genotypic, and is taken entirely by mouth. A single tablet regimen is used for adults with genotype 1-6 chronic hepatitis C virus (HCV) infection.[1]

Velpatasvir/sofosbuvir was developed by the pharmaceutical company Gilead Sciences and approved by US FDA in June 2016.[2]

Beacon Pharmaceuticals, Bangladesh, introduced a generic version product under the trade name of Sofosvel. Beacon got approval from the Directorate of Drug Administration, Ministry of Health and Family Welfare, People's Republic of Bangladesh.[3] Other Indian companies with similar licenses are expected to follow.[4]

References

  1. ↑ FDA Approves Epclusa, Drugs.com
  2. ↑ "FDA approves Epclusa for treatment of chronic Hepatitis C virus infection". Retrieved 14 July 2016.
  3. ↑ US’ Gilead faces competition from Bangladesh’s Beacon pharma, The Economic Times
  4. ↑ http://esofosbuvir.com/sofosvel-generic-hepatitis-c-medicine-genotypes/


This article is issued from Wikipedia - version of the 10/16/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.